<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEXCHLORPHENIRAMINE MALEATE</span><br/>(dex-klor-fen-eer'a-meen)<br/><span class="topboxtradename">Dexchlor, </span><span class="topboxtradename">Poladex T. D., </span><span class="topboxtradename">Polaramine, </span><span class="topboxtradename">Polargen<br/></span><b>Classifications:</b> <span class="classification">antihistamine (h<sub>1</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg tablets; 4 mg, 6 mg sustained release tablets; 2 mg/5 mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>Competes for H<sub>1</sub> receptor sites on cells thus blocking histamine release.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>H<sub>1</sub>-receptor antagonist and alkyl amine antihistamine. In common with other antihistamines, has anticholinergic properties and
         produces mild to moderate drowsiness and sedation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Perennial and seasonal allergic rhinitis, other manifestations of allergy, and vasomotor rhinitis. Also as adjunct to epinephrine
         in treatment of anaphylactic reactions.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to antihistamines of similar class; acute asthmatic attack, lower respiratory tract symptoms, newborns, premature
         infants. Safe use during pregnancy (category B) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Increased intraocular pressure; prostatic hypertrophy; hyperthyroidism; renal and cardiovascular disease; older adults.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 mg q46h or 46 mg of repeat-action tablets h.s. or q810h during the day<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>25 y,</i> 0.5 mg q46h (max: 3 mg/24 h); <i>611 y,</i> 1 mg q46h (max: 6 mg/24 h) or 4 mg of repeat-action tablets h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that sustained release form of drug is not chewed or crushed. It must be swallowed whole.</li>
<li>Give regular tablet whole or crushed and taken with fluid or mixed with food.</li>
<li>Give medication with food, water, or milk to lessen GI distress.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness</span>, dizziness, weakness, headache, excitation, neuritis, disturbed coordination, insomnia, euphoria, paresthesias. <span class="typehead">Special Senses:</span> Vertigo, tinnitus, acute labyrinthitis; blurred vision. <span class="typehead">CV:</span> Palpitation, tachycardia, hypotension, extrasystoles. <span class="typehead"> GI:</span>  Nausea, vomiting, anorexia, <span class="speceff-common">dry mouth,</span> constipation, diarrhea. <span class="typehead">Urogenital:</span> Difficulty in urinating, <span class="speceff-common">urinary retention,</span> urinary frequency, early menses. <span class="typehead">Hematologic:</span> <span class="speceff-life">Agranulocytosis</span> (rare), hemolytic or hypoplastic anemia. <span class="typehead">Skin:</span> Skin eruptions, photosensitivity. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>In common with other antihistamines, dexchlorpheniramine may interfere with <span class="alt">skin tests for allergy;</span> discontinue dexchlorpheniramine at least 72 h before tests.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span>, <span class="classification">mao inhibitors</span> compound CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> Small amounts distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine within 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation and take safety precautions, especially with older adult patients.</li>
<li>Monitor I&amp;O and assess for difficulty voiding (e.g., frequency or retention).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Swallow timed or sustained release tablet whole. Do not break, crush, or chew.</li>
<li>Do not drive or engage in other potentially hazardous activities until reaction to drug is known.</li>
<li>Ask physician about the use of alcohol, tranquilizers, sedatives, or other CNS depressants because the effects of dexchlorpheniramine
            will be additive.
         </li>
<li>Discontinue dexchlorpheniramine about 4 d before skin tests for allergies, since it can make test results inaccurate.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>